The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic, the popular diabetes drug widely used for weight loss, was among the 15 prescription drugs selected for Medicare price negotiations announced by President Joe Biden's administration on Friday (January 17),

Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.